Taiichi Hikichi
Overview
Explore the profile of Taiichi Hikichi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hikichi T, Agarie M, Kubo N, Yamauchi M
Retina
. 2020 Jan;
40(11):2158-2165.
PMID: 31922495
Purpose: To investigate predictors of recurrent exudation in choroidal neovascularization (CNV) of age-related macular degeneration on optical coherence tomography angiography (OCTA) images during an anti-vascular endothelium growth factor therapy-free period....
12.
Shimura M, Kitano S, Muramatsu D, Fukushima H, Takamura Y, Matsumoto M, et al.
Br J Ophthalmol
. 2019 Dec;
104(9):1209-1215.
PMID: 31784500
Background/aims: To investigate real-world outcomes for best-corrected visual acuity (BCVA) after 2-year clinical intervention for treatment-naïve, centr-involving diabetic macular oedema (DME). Methods: Retrospective analysis of longitudinal medical records obtained from...
13.
Hikichi T, Agarie M
Invest Ophthalmol Vis Sci
. 2019 Mar;
60(4):1088-1095.
PMID: 30901385
Purpose: To investigate macular vascular alterations by using optical coherence tomography angiography (OCTA) in patients with a history of long-term anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular...
14.
Yamashiro K, Mori K, Honda S, Kano M, Yanagi Y, Obana A, et al.
Sci Rep
. 2017 Aug;
7(1):9196.
PMID: 28835685
We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF treatment for exudative age-related macular degeneration (AMD) in a prospective cohort. Four hundred and sixty-one treatment-naïve AMD patients...
15.
Hikichi T
Br J Ophthalmol
. 2017 May;
102(1):97-101.
PMID: 28546150
Objective: To evaluate the 6-year outcomes of anti-VEGF (vascular endothelial growth factor) monotherapy for polypoidal choroidal vasculopathy (PCV). Methods: The charts of 66 eyes of 66 patients with newly diagnosed,...
16.
Hikichi T, Kitamei H, Shioya S
BMC Ophthalmol
. 2016 May;
16(1):55.
PMID: 27184489
Background: To evaluate the quantitative changes of retinal pigment epithelial (RPE) atrophy during 3-year follow-up period of ranibizumab monotherapy for polypoidal choroidal vasculopathy (PCV). Methods: We retrospectively reviewed consecutive 100...
17.
Hikichi T
BMC Ophthalmol
. 2015 Apr;
15:37.
PMID: 25881324
Background: To investigate the third-year results of ranibizumab monotherapy for polypoidal choroidal vasculopathy (PCV) in individualized treatment regimens based on the outcomes during 2 years. Methods: One hundred seventy-two consecutive...
18.
Hikichi T, Kitamei H, Shioya S
Br J Ophthalmol
. 2014 Dec;
99(6):817-22.
PMID: 25480464
Purpose: To determine predictors of 2-year outcomes after three, monthly, intravitreal ranibizumab (IVR) injections followed by as-needed injections for treatment-naive polypoidal choroidal vasculopathy (PCV). Methods: This trial included 85 Japanese...
19.
Hikichi T, Kitamei H, Shioya S, Higuchi M, Matsushita T, Kosaka S, et al.
Br J Ophthalmol
. 2014 Apr;
98(9):1201-4.
PMID: 24723615
Aim: To determine a correlation between changes in the subfoveal choroidal thickness and outcomes 1 year after ranibizumab therapy for polypoidal choroidal vasculopathy (PCV). Methods: We prospectively studied 89 consecutive...
20.
Hikichi T, Kitamei H, Kosaka S, Shioya S, Takami K
Clin Ophthalmol
. 2014 Mar;
8:477-81.
PMID: 24610999
Background: The purpose of this study was to determine the incidence of vitreous incarceration in sclerotomy after cannula removal during 23-gauge vitrectomy. Methods: Thirty-seven eyes underwent 23-gauge sutureless vitrectomy. Oblique...